Lecap Asset Management Ltd. Buys Shares of 45,970 Pfizer Inc. (NYSE:PFE)

Lecap Asset Management Ltd. acquired a new stake in Pfizer Inc. (NYSE:PFE - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 45,970 shares of the biopharmaceutical company's stock, valued at approximately $1,323,000.

Other institutional investors have also recently bought and sold shares of the company. Fulton Bank N.A. lifted its holdings in shares of Pfizer by 4.7% during the 3rd quarter. Fulton Bank N.A. now owns 176,239 shares of the biopharmaceutical company's stock worth $5,846,000 after acquiring an additional 7,991 shares during the period. Portside Wealth Group LLC bought a new stake in shares of Pfizer during the 2nd quarter worth approximately $2,072,000. Adage Capital Partners GP L.L.C. lifted its holdings in shares of Pfizer by 40.5% during the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 4,739,672 shares of the biopharmaceutical company's stock worth $157,215,000 after acquiring an additional 1,365,295 shares during the period. Brookstone Capital Management lifted its holdings in shares of Pfizer by 88.5% during the 3rd quarter. Brookstone Capital Management now owns 452,352 shares of the biopharmaceutical company's stock worth $14,109,000 after acquiring an additional 212,369 shares during the period. Finally, ETF Store Inc. lifted its holdings in shares of Pfizer by 12.0% during the 3rd quarter. ETF Store Inc. now owns 6,803 shares of the biopharmaceutical company's stock worth $214,000 after acquiring an additional 727 shares during the period. Institutional investors own 68.36% of the company's stock.

Pfizer Stock Down 1.8 %

Shares of PFE traded down $0.48 during trading hours on Friday, reaching $25.86. 43,034,056 shares of the stock traded hands, compared to its average volume of 35,130,948. The company has a current ratio of 0.91, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69. The stock has a fifty day simple moving average of $27.28 and a 200 day simple moving average of $28.91. Pfizer Inc. has a 52 week low of $25.61 and a 52 week high of $41.71. The company has a market cap of $146.43 billion, a price-to-earnings ratio of 71.83, a PEG ratio of 1.18 and a beta of 0.61.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, beating analysts' consensus estimates of ($0.19) by $0.29. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The company had revenue of $14.25 billion for the quarter, compared to analyst estimates of $14.37 billion. During the same period last year, the firm earned $1.14 earnings per share. The firm's revenue was down 41.3% on a year-over-year basis. On average, equities analysts forecast that Pfizer Inc. will post 2.22 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts recently commented on PFE shares. Argus downgraded shares of Pfizer from a "buy" rating to a "hold" rating in a research note on Friday, March 22nd. TD Cowen downgraded shares of Pfizer from an "outperform" rating to a "market perform" rating and set a $32.00 price objective for the company. in a research note on Thursday, January 4th. Guggenheim started coverage on shares of Pfizer in a research note on Friday, February 23rd. They issued a "buy" rating and a $36.00 price objective for the company. Finally, Cantor Fitzgerald reissued an "overweight" rating and issued a $45.00 price objective on shares of Pfizer in a research note on Monday, April 1st. Twelve equities research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and a consensus price target of $36.88.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.